Compare Moderna, Inc. (MRNA) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs AT&T Inc. — how do they compare? Moderna, Inc. trades at $213.71 (market cap $78.65B), while AT&T Inc. trades at $22.21 (market cap $170.42B). The key difference: AT&T Inc. is far larger — about 2.2× Moderna, Inc.'s market cap, and AT&T Inc. pays a 4.46% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and AT&T Inc. for 118 Days on average.
| MRNA | T | |
|---|---|---|
Market Cap | $78.65B | $170.42B |
Volume | 37,373,437 | 50,780,036 |
Sector | Health | Media |
52-Week High | $203.46 | $29.10 |
52-Week Low | $22.36 | $20.49 |
Typical Hold Time | 59 Days | 118 Days |
Enterprise Value | $74.80B | $315.74B |
Dividend Yield | — | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
AT&T (T) trades at $22.105, down 9.68% in the last session, reflecting market concerns despite strong fundamentals. The stock shows solid profitability with 16.94% net margin and attractive valuation at 8.21 P/E. Recent earnings beats and a $3 billion fiber deal with Corning highlight growth initiatives, while technical indicators show mixed signals with RSI at neutral levels.
The outlook remains balanced with analyst consensus at $27.50 target suggesting 24% upside, supported by fiber expansion and wireless growth. Key risks include heavy debt load at $118.44 billion and competitive pressures. The 4% dividend yield provides income support, but investors should monitor execution on debt reduction and revenue trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
